Development of MecVax, a Cross Protective Subunit Vaccine for ETEC

开发 ETEC 交叉保护亚单位疫苗 MecVax

基本信息

项目摘要

Project Summary Diarrhea is the second leading cause of death in children aged <5 years in developing countries, more than AIDS, malaria, and measles combined. Our long-term goal is to develop effective vaccines against diarrheal bacteria. The objective of this industrial partnership project is to combine expertise and leadership from academic vaccine research and industrial vaccine development and manufacturing to accelerate the development of MecVax, a multivalent cross-protective subunit vaccine for enterotoxigenic Escherichia coli (ETEC). ETEC bacteria are one of the top five causes of children's diarrhea and the most common cause of travelers' diarrhea. ETEC is listed as a category B priority pathogen (NIH) and a serious threat of antibiotic resistance (CDC), and causes >220 million diarrhea clinical cases annually, resulting in stunting and poor cognitive development in diarrheal children, 1,065,000 years lost due to disability (YLD), 6,894,000 years to disability-adjusted life-years (DALY), and about 100,000 deaths (many are children < 5 years). ETEC is also a primary cause of diarrhea in young animals and causes significant economic losses worldwide. Currently, there are no licensed vaccines against ETEC diarrhea. The development of effective vaccines for ETEC is a top priority for WHO, UNICEF, and many other public health institutions. By applying an innovative vaccinology platform, we have constructed two polyvalent proteins and developed a protein-based multivalent ETEC vaccine candidate, MecVax. MecVax is the only ETEC vaccine candidate that induces protective antibodies against both ETEC toxins (LT and STa) and the seven most important ETEC adhesins (CFA/I, CS1 - CS6). Since ETEC bacteria producing LT and/or STa toxin are associated with all ETEC diarrhea cases and strains expressing adhesin CFA/I or CS1 - CS6 cause > 66% of ETEC clinical cases, the synergy of antitoxin and anti-adhesin immunity from MecVax provides truly broad protection against ETEC children's diarrhea and travelers' diarrhea. MecVax is demonstrated to broadly protect against ETEC clinical diarrhea and colonization of small intestines preclinically. The central goal of this milestone-oriented vaccine development project is to optimize MecVax vaccine formulation, analytical development, and production processing. The rationale is that the completion of this application will identify MecVax optimal formulation, optimize upstream and downstream processing and analytical development, and manufacture vaccine cGLP products, - essential to accelerate MecVax development. To achieve these goals, we will 1) evaluate MecVax protection against ETEC adherence and enterotoxicity at different antigen doses, adjuvants, buffers, and shelving conditions, 2) optimize analytical assays and upstream and downstream processing, 3) manufacture and test MecVax master cell banks, and 4) perform product production engineering runs and submit MecVax pre-IND application. The positive impact is that an effective ETEC vaccine will save nearly 100,000 lives and prevent >200 million diarrheal clinical cases each year, and reduce long-term negative nutritional and developmental impacts.
项目摘要 腹泻是发展中国家5岁以下儿童死亡的第二大原因, 艾滋病,疟疾,和麻疹。我们的长期目标是开发有效的疫苗来对抗霍乱 细菌该工业伙伴关系项目的目标是将联合收割机的专门知识和领导能力结合起来, 学术疫苗研究和工业疫苗开发和制造,以加快 大肠杆菌多价交叉保护性亚单位疫苗MecVax的研制 (ETEC)。ETEC细菌是儿童腹泻的五大原因之一,也是最常见的原因。 旅行者腹泻ETEC被列为B类优先病原体(NIH),是抗生素的严重威胁 耐药性(CDC),每年导致> 2.2亿例腹泻临床病例,导致发育迟缓和贫困。 残疾儿童的认知发展,1,065,000年因残疾而损失(YLD),6,894,000年 残疾调整生命年(DALY),约100,000例死亡(许多是5岁以下儿童)。ETEC也是一个 这是幼畜腹泻的主要原因,并在全世界造成重大经济损失。 目前,没有针对ETEC腹泻的许可疫苗。有效疫苗的研制 ETEC是世卫组织、联合国儿童基金会和许多其他公共卫生机构的首要任务。通过应用创新的 在疫苗学平台上,我们构建了两种多价蛋白,并开发了一种基于蛋白的多价疫苗。 ETEC候选疫苗,MecVax。MecVax是唯一一种能够诱导保护性ETEC的候选疫苗。 针对ETEC毒素(LT和STa)和七种最重要的ETEC粘附素(CFA/I,CS 1- CS6)。由于产生LT和/或STa毒素的ETEC细菌与所有ETEC腹泻病例相关, 表达粘附素CFA/I或CS 1- CS6的菌株导致> 66%的ETEC临床病例,抗毒素的协同作用 MecVax的抗粘附素免疫力提供了真正广泛的保护,防止ETEC儿童腹泻, 旅行者腹泻MecVax被证明可广泛预防ETEC临床腹泻和定植 临床前的小肠这个里程碑式的疫苗开发项目的中心目标是 优化MecVax疫苗配方、分析开发和生产工艺。基本原理是 该应用程序完成将确定MecVax最佳配方,优化上游和下游 加工和分析开发,以及生产疫苗cGLP产品,-对于加速 MecVax开发。为了实现这些目标,我们将1)评估MecVax对ETEC依从性的保护 在不同抗原剂量、佐剂、缓冲液和搁置条件下的肠毒性,2)优化分析 检测和上游及下游处理,3)生产和检测MecVax主细胞库,以及4) 执行产品生产工程运行并提交MecVax pre-IND申请。 积极的影响是,有效的ETEC疫苗将挽救近10万人的生命,预防> 2亿人死亡。 每年减少临床病例,减少长期负面的营养和发育影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WEIPING ZHANG其他文献

WEIPING ZHANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WEIPING ZHANG', 18)}}的其他基金

A broadly protective subunit vaccine against enterotoxigenic Escherichia coli (ETEC) associated diarrhea
一种针对产肠毒素大肠杆菌 (ETEC) 相关腹泻的广泛保护性亚单位疫苗
  • 批准号:
    9280788
  • 财政年份:
    2016
  • 资助金额:
    $ 117.07万
  • 项目类别:
A broadly protective subunit vaccine against enterotoxigenic Escherichia coli (ETEC) associateddiarrhea
一种针对产肠毒素大肠杆菌 (ETEC) 相关腹泻的广泛保护性亚单位疫苗
  • 批准号:
    9912501
  • 财政年份:
    2016
  • 资助金额:
    $ 117.07万
  • 项目类别:
A broadly protective subunit vaccine against enterotoxigenic Escherichia coli (ETEC) associated diarrhea
一种针对产肠毒素大肠杆菌 (ETEC) 相关腹泻的广泛保护性亚单位疫苗
  • 批准号:
    9174335
  • 财政年份:
    2016
  • 资助金额:
    $ 117.07万
  • 项目类别:
A broadly protective subunit vaccine against enterotoxigenic Escherichia coli (ETEC) associateddiarrhea
一种针对产肠毒素大肠杆菌 (ETEC) 相关腹泻的广泛保护性亚单位疫苗
  • 批准号:
    9922200
  • 财政年份:
    2016
  • 资助金额:
    $ 117.07万
  • 项目类别:
A subunit vaccine for enterotoxigenic E. coli associated traveler's diarrhea
一种针对产肠毒素大肠杆菌相关旅行者腹泻的亚单位疫苗
  • 批准号:
    8700107
  • 财政年份:
    2014
  • 资助金额:
    $ 117.07万
  • 项目类别:
A subunit vaccine for enterotoxigenic E. coli associated traveler's diarrhea
一种针对产肠毒素大肠杆菌相关旅行者腹泻的亚单位疫苗
  • 批准号:
    8838707
  • 财政年份:
    2014
  • 资助金额:
    $ 117.07万
  • 项目类别:
Determining vaccine candidacy of LT and STa toxoid fusions against enterotoxigeni
确定针对肠毒素的 LT 和 STa 类毒素融合疫苗的候选资格
  • 批准号:
    7860302
  • 财政年份:
    2009
  • 资助金额:
    $ 117.07万
  • 项目类别:
Determining vaccine candidacy of LT and STa toxoid fusions against enterotoxigeni
确定针对肠毒素的 LT 和 STa 类毒素融合疫苗的候选资格
  • 批准号:
    7706959
  • 财政年份:
    2009
  • 资助金额:
    $ 117.07万
  • 项目类别:
Pathogenesis of EAST1 toxin in ETEC associated diarrhea disease
EAST1 毒素在 ETEC 相关腹泻病中的发病机制
  • 批准号:
    7363893
  • 财政年份:
    2008
  • 资助金额:
    $ 117.07万
  • 项目类别:
Development of an additive model to study the significance of heat-labile and hea
开发加性模型来研究热不稳定和热的重要性
  • 批准号:
    7235838
  • 财政年份:
    2007
  • 资助金额:
    $ 117.07万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 117.07万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 117.07万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 117.07万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 117.07万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 117.07万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 117.07万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 117.07万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 117.07万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 117.07万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 117.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了